This is an update to the fda drug safety communication: safety clinical trial shows possible increased risk of cancer with weight-loss medicine belviq, belviq xr (lorcaserin) issued on january 14. Belviq recall reimbursement. Belviq recall following the results of a recent safety trial, the food and drug administration (fda) has issued a warning that the weight loss drug lorcaserin (belviq) may increase the risk of cancer therefore, the agency is issuing a belviq recall about belviq according to the cdc, around 40% of americans are obese.
belviq recall reimbursement
